natgillin/translations-raw huggingface dataset:
EU/2/10/115/016 (90 mg, 3 tablets) EU/2/10/115/017 (90 mg, 6 tablets) EU/2/10/115/018 (140 mg, 3 tablets) EU/2/10/115/019 (140 mg, 6 tablets) EU/2/10/115/020 (180 mg, 3 tablets) EU/2/10/115/021 (180 mg, 6 tablets) EU/2/10/115/011 (270 mg, 3 tablets) EU/2/10/115/001 (270 mg, 6 tablets) EU/2/10/115/012 (425 mg, 3 tablets) EU/2/10/115/003 (425 mg, 6 tablets) EU/2/10/115/013 (665 mg, 3 tablets) EU/2/10/115/005 (665 mg, 6 tablets) EU/2/10/115/014 (1040 mg, 3 tablets) EU/2/10/115/007 (1040 mg, 6 tablets) EU/2/10/115/015 (1620 mg, 3 tablets) EU/2/10/115/009 (1620 mg, 6 tablets)
EU/2/10/115/016 (90 mg, 3 tablete) EU/2/10/115/017 (90 mg, 6 tableta) EU/2/10/115/018 (140 mg, 3 tablete) EU/2/10/115/019 (140 mg, 6 tableta) EU/2/10/115/020 (180 mg, 3 tablete) EU/2/10/115/021 (180 mg, 6 tableta) EU/2/10/115/011 (270 mg, 3 tablete) EU/2/10/115/001 (270 mg, 6 tableta) EU/2/10/115/012 (425 mg, 3 tablete) EU/2/10/115/003 (425 mg, 6 tableta) EU/2/10/115/013 (665 mg, 3 tablete) EU/2/10/115/005 (665 mg, 6 tableta) EU/2/10/115/014 (1040 mg, 3 tablete) EU/2/10/115/007 (1040 mg, 6 tableta) EU/2/10/115/015 (1620 mg, 3 tablete) EU/2/10/115/009 (1620 mg, 6 tableta)
EU/2/10/117/003 (2 vials)
(50 bočica) (2 bočice)
EU/2/11/129/003 5 x 1 dose
EU/2/11/129/003 5 x 1 doza
EU/2/11/129/004 10 x 1 dose
EU/2/11/129/004 10 x 1 doza
EU/2/11/130/001
EMEA/V/C/ 002334
EU/2/11/130/002
EMEA/V/C/ 002334
EU/2/11/130/003
EMEA/V/C/ 002334
EU/2/11/131/001
EMEA/V/C/ 2235
EU/2/11/134/013 2.5 mg 20 tablets
EU/2/11/134/013 2,5 mg, 20 tablets
EU/2/11/134/014 2.5 mg, 100 tablets
EU/2/11/134/014 2,5 mg, 100 tablets
EU/2/12/142/001 (1 x 30 tablets, 2.5 mg/20 mg)
EU/2/12/142/001 (1 x 30 tableta, 2,5 mg/20 mg)
EU/2/12/142/002 (1 x 90 tablets, 2.5 mg/20 mg)
EU/2/12/142/002 (1 x 90 tableta, 2,5 mg/20 mg)
EU/2/12/142/003 (1 x 30 tablets, 5 mg/40 mg)
EU/2/12/142/003 (1 x 30 tableta, 5 mg/40 mg)
EU/2/12/142/004 (1 x 90 tablets, 5 mg/40 mg)
EU/2/12/142/004 (1 x 90 tableta, 5 mg/40 mg)
EU/2/12/142/005 (1 x 30 tablets, 10 mg/80 mg)
EU/2/12/142/005 (1 x 30 tableta, 10 mg/80 mg)
EU/2/12/142/006 (1 x 90 tablets, 10 mg/80 mg)
EU/2/12/142/006 (1 x 90 tableta, 10 mg/80 mg)
EU/2/12/147/001 100 tablets
EU/2/12/147/001 100 tableta
EU/2/12/147/002 250 tablets
EU/2/12/147/002 250 tableta
EU/2/12/147/003 100 tablets
EU/2/12/147/003 100 tableta
EU/2/12/147/004 250 tablets
EU/2/12/147/004 250 tableta
EU/2/13/149/001 PET bottle of 50 ml EU/2/13/149/002 PET bottle of 100 ml
EU/2/13/149/001 PET bočica od 50 ml EU/2/13/149/002 PET bočica od 100 ml
EU/2/13/149/002 PET bottle
EU/2/13/149/002 PET bočica
EU/2/13/151/0001 (10 vials) EU/2/13/151/0002 (5 pre-filled- syringes) EU/2/13/151/0003 (10 pre-filled- syringes)
EU/2/13/151/0001 ( 10 bočica) EU/2/13/151/0002 (5 napunjenih šprica) EU/2/13/151/0003 (10 napunjenih šprica)
EU/2/13/154/001 (1 x 20 tablets, 3.6 mg)
EU/2/13/154/001 (1 x 20 tableta, 3,6 mg)
EU/2/13/154/001 (1 x 20 tablets, 3.6 mg) EU/2/13/154/007 (1 x 50 tablets, 3.6 mg)
EU/2/13/154/001 (1 x 20 tableta, 3,6 mg) EU/2/13/154/007 (1 x 50 tableta, 3,6 mg)
EU/2/13/154/002 (1 x 100 tablets, 3.6 mg)
EU/2/13/154/002 (1 x 100 tableta, 3,6 mg)
EU/2/13/154/003 (1 x 20 tablets, 5.4 mg)
EU/2/13/154/003 (1 x 20 tableta, 5,4 mg)
EU/2/13/154/004 (1 x 100 tablets, 5.4 mg)
EU/2/13/154/004 (1 x 100 tableta, 5,4 mg)
EU/2/13/154/005 (1 x 20 tablets, 16 mg)
EU/2/13/154/005 (1 x 20 tableta, 16 mg)
EU/2/13/154/006 (1 x 100 tablets, 16 mg)
EU/2/13/154/006 (1 x 100 tableta, 16 mg)
EU/2/13/154/007 (1 x 50 tablets, 3.6 mg)
EU/2/13/154/007 (1 x 50 tableta, 3,6 mg)
EU/2/13/154/008 (1 x 50 tablets, 5.4 mg)
EU/2/13/154/008 (1 x 50 tableta, 5,4 mg)
EU/2/13/154/009 (1 x 50 tablets, 16 mg)
EU/2/13/154/009 (1 x 50 tableta, 16 mg)
EU/2/13/154/010 (20 tablets, 3.6 mg)
EU/2/13/154/010 (20 tableta, 3.6 mg)
EU/2/13/154/011 (50 tablets, 3.6 mg)
EU/2/13/154/011 (50 tableta, 3.6 mg)
EU/2/13/154/012 (100 tablets, 3.6 mg)
EU/2/13/154/002 (1 x 100 tableta, 3,6 mg)
EU/2/13/154/012 (100 tablets, 3.6 mg)
EU/2/13/154/012 (100 tableta, 3.6 mg)
EU/2/13/154/013 (20 tablets, 5.4 mg)
EU/2/13/154/003 (1 x 20 tableta, 5,4 mg)
EU/2/13/154/013 (20 tablets, 5.4 mg)
EU/2/13/154/013 (20 tableta, 5.4 mg)
EU/2/13/154/014 (50 tablets, 5.4 mg)
EU/2/13/154/008 (1 x 50 tableta, 5,4 mg)
EU/2/13/154/014 (50 tablets, 5.4 mg)
EU/2/13/154/014 (50 tableta, 5.4 mg)
EU/2/13/154/015 (100 tablets, 5.4 mg)
EU/2/13/154/004 (1 x 100 tableta, 5,4 mg)
EU/2/13/154/015 (100 tablets, 5.4 mg)
EU/2/13/154/015 (100 tableta, 5.4 mg)
EU/2/13/154/016 (20 tablets, 16 mg)
EU/2/13/154/005 (1 x 20 tableta, 16 mg)
EU/2/13/154/016 (20 tablets, 16 mg)
EU/2/13/154/016 (20 tableta, 16 mg)
EU/2/13/154/017 (50 tablets, 16 mg)
EU/2/13/154/009 (1 x 50 tableta, 16 mg)
EU/2/13/154/017 (50 tablets, 16 mg)
EU/2/13/154/017 (50 tableta, 16 mg)
EU/2/13/154/018 (100 tablets, 16 mg)
EU/2/13/154/006 (1 x 100 tableta, 16 mg)
EU/2/13/154/018 (100 tablets, 16 mg)
EU/2/13/154/018 (100 tableta, 16 mg)
EU/2/13/155/001 (1 tablet, 270 mg/4.5 mg)
EU/2/13/155/001 (1 tableta, 270 mg/4,5 mg)
EU/2/13/156/012
Pakovanje
EU/2/13/156/018
Pakovanje
EU/2/13/156/024
Pakovanje
EU/2/13/156/030
Pakovanje
EU/2/13/157/001–009
EU/2/13/157/001-009
EU/2/13/158/009
Pakovanje
EU/2/13/158/017
Pakovanje
EU/2/13/158/025
Pakovanje
EU/2/13/159/001–012
EU2/13/159/001–012
EU/2/14/162/001–002
EU/2/14/162/001-002
EU/2/14/165/001 (1 spot-on applicator) EU/2/14/165/002 (3 spot-on applicators) EU/2/14/165/006 (4 spot-on applicators) EU/2/14/165/003 (6 spot-on applicators) EU/2/14/165/004 (12 spot-on applicators) EU/2/14/165/007 (24 spot-on applicators) EU/2/14/165/005 (72 spot-on applicators)
EU/2/14/165/001 (1 aplikator za nakapavanje) EU/2/14/165/002 (3 aplikatora za nakapavanje) 4U/2/14/165/006 (4 aplikatora za nakapavanje) EU/2/14/165/003 (6 aplikatora za nakapavanje) EU/2/14/165/004 (12 aplikatora za nakapavanje) EU/2/14/165/007 (24 aplikatora za nakapavanje) EU/2/14/165/005 (72 aplikatora za nakapavanje)
EU/2/14/166/007
Pakovanje
EU/2/14/167/004
Pakovanje
EU/2/14/167/007
Pakovanje
EU/2/14/170/0001 (2 tubes) EU/2/14/170/0002 (12 tubes)
EU/2/14/170/0001 (2 tube) EU/2/14/170/0002 (12 tuba)
EU/2/14/170/0003 (20 tubes)
EU/2/14/170/0003 (20 tuba)
EU/2/14/170/0004 (40 tubes)
EU/2/14/170/0004 (40 tuba)
EU/2/14/174/001–004
EU/2/14/174/001-004
EU/2/14/175/001–010
EU/2/14/175/001-010
EU/2/14/175/005 (500 ml) EU/2/14/175/006 (10x20 ml) EU/2/14/175/007 (10x50 ml) EU/2/14/175/008 (10x100 ml) EU/2/14/175/009 (10x200 ml) EU/2/14/175/010 (10x500 ml)
EU/2/00/000/005 (500 ml) EU/2/00/000/006 (10x20 ml) EU/2/00/000/007 (10x50 ml) EU/2/00/000/008 (10x100 ml) EU/2/00/000/009 (10x200 ml) EU/2/00/000/010 (10x500 ml)
EU/2/14/176/001 5 doses and 10 ml EU/2/14/176/002 5 doses and 10 ml (4 x) EU/2/14/176/003 5 doses and 10 ml (6 x) EU/2/14/176/004 5 doses and 10 ml (10 x) EU/2/14/176/005 10 doses and 20 ml EU/2/14/176/006 10 doses and 20 ml (4 x) EU/2/14/176/007 10 doses and 20 ml (6 x) EU/2/14/176/008 10 doses and 20 ml (10 x) EU/2/14/176/009 25 doses and 50 ml EU/2/14/176/010 25 doses and 50 ml (4 x) EU/2/14/176/011 25 doses and 50 ml (6 x) EU/2/14/176/012 25 doses and 50 ml (10 x) EU/2/14/176/013 50 doses and 100 ml EU/2/14/176/014 50 doses and 100 ml (4 x) EU/2/14/176/015 50 doses and 100 ml (6 x) EU/2/14/176/016 50 doses and 100 ml (10 x)
EU/2/14/176/001 5 doza i 10 ml EU/2/14/176/002 5 doza i 10 ml (4 x) EU/2/14/176/003 5 doza i 10 ml (6 x) EU/2/14/176/004 5 doza i 10 ml (10 x) EU/2/14/176/005 10 doza i 20 ml EU/2/14/176/006 10 doza i 20 ml (4 x) EU/2/14/176/007 10 doza i 20 ml (6 x) EU/2/14/176/008 10 doza i 20 ml (10 x) EU/2/14/176/009 25 doza i 50 ml EU/2/14/176/010 25 doza i 50 ml (4 x) EU/2/14/176/011 25 doza i 50 ml (6 x) EU/2/14/176/012 25 doza i 50 ml (10 x) EU/2/14/176/013 50 doza i 100 ml EU/2/14/176/014 50 doza i 100 ml (4 x) EU/2/14/176/015 50 doza i 100 ml (6 x) EU/2/14/176/016 50 doza i 100 ml (10 x)
EU/2/14/176/011
Pakovanje
EU/2/14/176/013 50 doses
EU/2/14/176/013 50 doza
EU/2/14/176/014 4 x 50 doses
EU/2/14/176/014 4 x 50 doza
EU/2/14/176/015 6 x 50 doses
EU/2/14/176/015 6 x 50 doza
EU/2/14/176/016 10 x 50 doses
EU/2/14/176/016 10 x 50 doza
EU/2/14/179/001 (10 doses)
EU/2/14/179/001 (10 doza)
EU/2/14/179/002 (50 doses)
EU/2/14/179/002 (50 doza)
EU/2/15/181/001 (1 x 3 ml oral syringe)
EU/2/15/181/001 (štrcaljka za oralnu primjenu, 1 x 3 ml)
EU/2/15/184/001 30 tablets of 0.75 mg EU/2/15/184/002 100 tablets of 0.75 mg EU/2/15/184/003 30 tablets of 3 mg EU/2/15/184/004 100 tablets of 3 mg EU/2/15/184/005 30 tablets of 7.5 mg EU/2/15/184/006 100 tablets of 7.5 mg EU/2/15/184/007 30 tablets of 18 mg EU/2/15/184/008 100 tablets of 18 mg
EU/2/15/184/001 30 tableta od 0,75 mg EU/2/15/184/002 100 tableta od 0,75 mg EU/2/15/184/003 30 tableta od 3 mg EU/2/15/184/004 100 tableta od 3 mg EU/2/15/184/005 30 tableta od 7,5 mg EU/2/15/184/006 100 tableta od 7,5 mg EU/2/15/184/007 30 tableta od 18 mg EU/2/15/184/008 100 tableta od 18 mg
EU/2/15/185/001 (1 x 30 tablets, 1.25 mg/2.5 mg)
EU/2/15/185/001 (1 x 30 tableta, 1,25 mg/2,5 mg)
EU/2/15/185/002 (1 x 60 tablets, 1.25 mg/2.5 mg)
EU/2/15/185/002 (1 x 60 tableta, 1,25 mg/2,5 mg)
EU/2/15/185/003 (1 x 30 tablets, 5 mg/10 mg)
EU/2/15/185/003 (1 x 30 tableta, 5 mg/10 mg)
EU/2/15/185/004 (1 x 60 tablets, 5 mg/10 mg)
EU/2/15/185/004 (1 x 60 tableta, 5 mg/10 mg)
EU/2/15/191/001 (5 mg, 1 tablet) EU/2/15/191/002 (5 mg, 3 tablets) EU/2/15/191/003 (5 mg, 6 tablets) EU/2/15/191/004 (10 mg, 1 tablet) EU/2/15/191/005 (10 mg, 3 tablets) EU/2/15/191/006 (10 mg, 6 tablets)
EU/2/15/191/001 (5 mg, 1 tableta) EU/2/15/191/002 (5 mg, 3 tablete) EU/2/15/191/003 (5 mg, 6 tableta) EU/2/15/191/004 (10 mg, 1 tableta) EU/2/15/191/005 (10 mg, 3 tablete) EU/2/15/191/006 (10 mg, 6 tableta) EU/2/15/191/007 (20 mg, 1 tableta) EU/2/15/191/008 (20 mg, 3 tablete)
EU/2/15/191/007 (20 mg, 1 tablet) EU/2/15/191/008 (20 mg, 3 tablets) EU/2/15/191/009 (20 mg, 6 tablets) EU/2/15/191/010 (40 mg, 1 tablet) EU/2/15/191/011 (40 mg, 3 tablets) EU/2/15/191/012 (40 mg, 6 tablets) EU/2/15/191/013 (80 mg, 1 tablet) EU/2/15/191/014 (80 mg, 3 tablets) EU/2/15/191/015 (80 mg, 6 tablets) EU/2/15/191/016 (120 mg, 1 tablet) EU/2/15/191/017 (120 mg, 3 tablets) EU/2/15/191/018 (120 mg, 6 tablets)
EU/2/15/191/009 (20 mg, 6 tableta) EU/2/15/191/010 (40 mg, 1 tableta) EU/2/15/191/011 (40 mg, 3 tablete) EU/2/15/191/012 (40 mg, 6 tableta) EU/2/15/191/013 (80 mg, 1 tableta) EU/2/15/191/014 (80 mg, 3 tablete) EU/2/15/191/015 (80 mg, 6 tableta) EU/2/15/191/016 (120 mg, 1 tableta) EU/2/15/191/017 (120 mg, 3 tablete) EU/2/15/191/018 (120 mg, 6 tableta)
EU/2/16/195/001 1 dose
EU/2/16/195/001 1 doza
EU/2/16/195/002 4 doses
EU/2/16/195/002 4 doze
EU/2/16/195/003 5 doses
EU/2/16/195/003 5 doza
EU/2/16/195/004 10 doses
EU/2/16/195/004 10 doza
EU/2/16/195/006 25 doses
EU/2/16/195/006 25 doza
EU/2/16/195/007 50 doses
EU/2/16/195/007 50 doza
EU/2/16/195/008 100 doses
EU/2/16/195/008 100 doza
EU/2/96/001/003 20 ml Glass EU/2/96/001/006 20 ml PET
EU/2/96/001/003 20 ml Staklo EU/2/96/001/006 20 ml PET
EU/2/96/001/004 50 ml Glass EU/2/96/001/007 50 ml PET
EU/2/96/001/004 50 ml Staklo EU/2/96/001/007 50 ml PET
EU/2/96/001/005 100 ml Glass EU/2/96/001/008 100 ml PET
EU/2/96/001/005 100 ml Staklo EU/2/96/001/008 100 ml PET
EU/2/97/004/001 1 x 100 ml
EU/2/97/004/001 100 ml
EU/2/97/004/035 1 x 20 ml
EU/2/97/004/035 20 ml
EU/2/97/004/037 1 x 50 ml
EU/2/97/004/037 50 ml
EU/2/97/004/045 252 tablets
EU/2/97/004/045 252 tablete
EU/2/97/004/048 252 tablets
EU/2/97/004/048 252 tablete
EU/2/98/008/002 20 ml vial.
EU/2/98/008/002 bočica od 20 ml.
EU/2/98/008/003 50 ml vial.
EU/2/98/008/003 bočica od 50 ml.
EU/2/98/008/004 100 ml vial.
EU/2/98/008/004 bočica od 100 ml.
EU/2/99/014/002 (45 mg - 3 pipettes) EU/2/99/014/008 (45 mg - 6 pipettes) EU/2/99/014/013 (60 mg - 3 pipettes) EU/2/99/014/014 (60 mg - 6 pipettes)
EU/2/99/014/002 (45 mg - 3 piptete) EU/2/99/014/008 (45 mg - 6 pipeta) EU/2/99/014/013 (60 mg - 3 pipete) EU/2/99/014/014 (60 mg - 6 pipete)
EU/216/195/005 20 doses
EU/2/16/195/005 20 doza
EU/I/02/212/001 2 film-coated tablets EU/I/02/212/002 10 film-coated tablets EU/I/02/212/003 14 film-coated tablets EU/I/02/212/004 20 film-coated tablets EU/I/02/212/005 28 film-coated tablets EU/I/02/212/006 30 film-coated tablets EU/I/02/212/007 50 film-coated tablets EU/I/02/212/008 56 film-coated tablets EU/I/02/212/009 100 film-coated tablets
EU/1/02/212/001 2 filmom obložene tablete EU/1/02/212/002 10 filmom obloženih tableta EU/1/02/212/003 14 filmom obloženih tableta EU/1/02/212/004 20 filmom obloženih tableta EU/1/02/212/005 28 filmom obloženih tableta EU/1/02/212/006 30 filmom obloženih tableta EU/1/02/212/007 50 filmom obloženih tableta EU/1/02/212/008 56 filmom obloženih tableta EU/1/02/212/009 100 filmom obloženih tableta
EU/I/02/212/010 2 film-coated tablets EU/I/02/212/011 30 film-coated tablets EU/I/02/212/012 100 film-coated tablets
EU/1/02/212/010 2 filmom obložene tablete EU/1/02/212/011 30 filmom obloženih tableta EU/1/02/212/012 100 filmom obloženih tableta
EU/I/02/212/013 2 film-coated tablets EU/I/02/212/014 10 film-coated tablets EU/I/02/212/015 14 film-coated tablets EU/I/02/212/016 20 film-coated tablets EU/I/02/212/017 28 film-coated tablets EU/I/02/212/018 30 film-coated tablets EU/I/02/212/019 50 film-coated tablets EU/I/02/212/020 56 film-coated tablets EU/I/02/212/021 100 film-coated tablets
EU/1/02/212/013 2 filmom obložene tablete EU/1/02/212/014 10 filmom obloženih tableta EU/1/02/212/015 14 filmom obloženih tableta EU/1/02/212/016 20 filmom obloženih tableta EU/1/02/212/017 28 filmom obloženih tableta EU/1/02/212/018 30 filmom obloženih tableta EU/1/02/212/019 50 filmom obloženih tableta EU/1/02/212/020 56 filmom obloženih tableta EU/1/02/212/021 100 filmom obloženih tableta
EU/I/02/212/022 2 film-coated tablets EU/I/02/212/023 30 film-coated tablets EU/I/02/212/024 100 film-coated tablets
EU/1/02/212/022 2 filmom obložene tablete EU/1/02/212/023 30 filmom obloženih tableta EU/1/02/212/024 100 filmom obloženih tableta
EUCAST Breakpoints
Granične vrijednosti po EUCAST-u
EUCAST ECOFF values:
EUCAST ECOFF vrijednosti za vrste roda Aspergillus:
EUCAST MIC breakpoints are defined for the following species (susceptible S; resistant R):
Prema EUCAST-u (European Committee on Antimicrobial Susceptibility Testing) granične vrijednosti minimalnih inhibitornih koncentracija (MIK) utvrĎene su za sljedeće vrste (S - osjetljiva; R - rezistentna):
Eucreas 50 mg/850 mg film-coated tablets are yellow, oval tablets with “NVR” on one side and “SEH” on the other.
Eucreas 50 mg/850 mg filmom obložene tablete su žute, ovalne tablete s oznakom „NVR” na jednoj strain i „SHE” na drugoj strani.
Eucreas is available in packs containing 10, 30, 60, 120, 180 or 360 film-coated tablets and in multi- packs containing 120 (2x60), 180 (3x60) or 360 (6x60) film-coated tablets.
Eucreas je dostupan u pakiranjima od 10, 30, 60, 120, 180 ili 360 filmom obloženih tableta i u višestrukim pakiranjima od 120 (2x60), 180 (3x60) ili 360 (6x60) filmom obloženih tableta.
Eucreas is indicated in combination with a sulphonylurea (i.e. triple combination therapy) as an adjunct to diet and exercise in adult patients inadequately controlled with metformin and a sulphonylurea.
Eucreas je indiciran u kombinaciji sa sulfonilurejom (tj. trojna kombinirana terapija) kao dodatak dijeti i tjelovježbi u odraslih bolesnika u kojih je kontrola nedostatna s metforminom i sulfonilurejom.
Eucreas is indicated in the treatment of adult patients who are unable to achieve sufficient glycaemic control at their maximally tolerated dose of oral metformin alone or who are already treated with the combination of vildagliptin and metformin as separate tablets.
Eucreas je indiciran u liječenju odraslih bolesnika u kojih se ne može postići zadovoljavajuća kontrola glikemije primjenom oralnog metformina u maksimalno podnošljivoj dozi ili u bolesnika koji se već liječe kombinacijom odvojenih tableta vildagliptina i metformina.
Eucreas is indicated in the treatment of type 2 diabetes mellitus:
Eucreas je indiciran u liječenju šećerne bolesti tipa 2:
Eucreas is indicated in triple combination therapy with insulin as an adjunct to diet and exercise to improve glycaemic control in adult patients when insulin at a stable dose and metformin alone do not provide adequate glycaemic control.
Eucreas je indiciran u trojnoj kombiniranoj terapiji sa inzulinom kao dodatak dijeti i tjelovježbi za poboljšanje kontrole glikemije u odraslih bolesnika u kojih stabilna doza inzulina i metformina ne omogućuju odgovarajuću kontrolu glikemije.
Eucreas is used to treat adult patients with type 2 diabetes.
Eucreas se primjenjuje za liječenje bolesnika sa šećernom bolešću tipa 2.
Eucreas should not be used in patients with creatinine clearance < 60 ml/min (see sections 4.3, 4.4 and 5.2).
Eucreas se ne smije primjenjivati u bolesnika s klirensom kreatinina <60 ml/min (vidjeti dijelove 4.3, 4.4 i 5.2).
EULAR Response (%)
EULAR odgovor (%)
EULAR Response (Good/Moderate)
EULAR odgovor (dobar/umjeren)
Eumelanin contributes to photoprotection through different mechanisms including: strong broad band absorption of UV and visible light, where eumelanin acts as a filter
Eumelanin doprinosi fotozaštiti putem različitih mehanizama uključujući: snažnu širokopojasnu apsorpciju UV i vidljivog svjetla, pri čemu eumelanin djeluje kao filtar
euphoria (feeling of extreme happiness), disorientation,
euforija (izraženi osjećaj sreće), gubitak orijentacije,
euphoria (feeling of extreme happiness), disorientation,
euforija (osjećaj ekstremne sreće), dezorijentiranost,
euphoria (feeling of extreme happiness), feeling confused
euforija (osjećaj ekstremne sreće), osjećaj smetenosti
Euphoric mood, confusion, irritability, disorientation, insomnia, libido decreased
euforično raspoloženje, konfuzija, razdražljivost, dezorijentacija, nesanica, smanjen libido
Eur J Cancer Clin Oncol 1982; 18: 905-910.), to a maximum dose of 150 mg.
Eur J Cancer Clin Oncol 1982; 18: 905-910.), a maksimalna doza iznosi 150 mg.
Eur. added.
Eur.
Eur. compliance.
Eur.).
Eur. monograph 0063.
Eur.) 0063.
Eur. potency test
Eur testu potencije
Eur. potency test
Eur. testu potencije.
Eur. units
Eur. jedinica
Eur. units 3,200 Ph.
Eur. jedinica 3200 Ph.
Eur. units 4,800 Ph.
Eur. jedinica proteolitička aktivnost: ne manje od 410 Ph.
Eur. units amylase: not less than 1,600 Ph.
Eur. jedinica amilazu: ne manje od 1600 Ph.
Eur. units amylase: not less than 3,200 Ph.
Eur. jedinica amilazu: ne manje od 3200 Ph.
Eur. units protease: not less than 130 Ph.
Eur. jedinica proteazu: ne manje od 130 Ph.
Eur. units protease: not less than 270 Ph.
Eur. jedinica proteazu: ne manje od 270 Ph.
Eur.) borosilicate glass vial of 10 ml or 50 ml with a bromobutyl rubber stopper sealed with aluminum crimp caps.
Eur.) borosilikatne staklene bočice od 10 ml za 2500 i 5000 doza i 50 ml za 10000 i 20000 doza s brombutilnim gumenim čepom i aluminijskom kapicom.
Eur.) borosilicate glass vialof 10 ml for 2,500 and 5,000 dose-presentations and 50 ml for 10,000 and 20,000 dose-presentations with a bromobutyl rubber stopper sealed with aluminum crimp caps.
Eur.) borosilikatna staklena bočica od 10 ml za 2500 i 5000 doza i 50 ml za 10000 i 20000 doza s brombutilnim gumenim čepom i aluminijskom kapicom.
Eurartesim 160 mg/20 mg film-coated tablets piperaquine tetraphosphate/artenimol
Eurartesim 160 mg/20 mg filmom obložene tablete piperakintetrafosfat/artenimol
Eurartesim 160 mg/20 mg film-coated tablets.
Eurartesim 160 mg/20 mg filmom obložene tablete
Eurartesim 320 mg/40 mg film-coated tablets
Eurartesim 320 mg/40 mg filmom obložene tablete
Eurartesim 320 mg/40 mg film-coated tablets piperaquine tetraphosphate / artenimol
Eurartesim 320 mg/40 mg filmom obložene tablete piperakintetrafosfat/artenimol
Eurartesim 320 mg/40 mg film-coated tablets.
Eurartesim 320 mg/40 mg filmom obložene tablete
Eurartesim must not be used in pregnancy if your doctor can give you an alternative medicine.
Eurartesim se ne smije uzimati tijekom trudnoće ako Vam liječnik može dati drugi lijek.
Eurartesim should not be used during pregnancy in situations where other suitable and effective anti- malarials are available (see section 4.4).
Eurartesim se ne smije primjenjivati tijekom trudnoće u situacijama kad su dostupni drugi pogodni i učinkoviti antimalarici (vidjeti dio 4.4).
Eurartesim should not be used during pregnancy in situations where other suitable and effective antimalarials are available (see section 4.6).
Eurartesim se ne smije primjenjivati tijekom trudnoće u situacijama kad su dostupni drugi pogodni i učinkoviti antimalarici (vidjeti dio 4.6).
Europe,
Europa,
Europe, Asia/ Oceania, Latin America
Azija/ Oceanija, Latinska
Europe, Asia/ Oceania, Latin America
Europa, Azija/ Oceanija, Latinska Amerika
Europe, Asia/Oceania
Europa, Azija/ Oceanija
European Knowledge Centre, Mosquito Way, Hatfield, Herfordshire, AL10 9SN, United Kingdom
European Knowledge Centre, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, Velika Britanija
European Medicines Agency reflection paper on criteria for requiring one additional five year renewal (EMEA/CVMP/430630/2006)
Dokument Europske agencije za lijekove o uvjetima za jedno dodatno petogodišnje produženje (EMEA/CVMP/430630/2006)
European Retrospective Study (2004)
Europsko retrospektivno
Eurovet Animal Health B.V. Handelsweg 25,
Eurovet Animal Health B.V., Handelsweg 25,
Evalon suspension and solvent for oral spray for chickens
Evalon suspenzija i otapalo za peroralni sprej za piliće
Evalon suspension for oral spray for chickens.
Evalon suspenzija za peroralni sprej za piliće.
Evaluable subjects are defined as those who have reached the specified time point at the time of the interim analysis. pTVR: post-transplant virologic response (HCV RNA <LLOQ at 12 weeks post-procedure).
Ispitanici koji su se mogli procijeniti definirani su kao oni koji su postigli određenu vremensku točku u vrijeme privremene analize. pTVR: virološki odgovor nakon transplantacije (HCV RNK < donje granice kvantifikacije u 12. tjednu nakon postupka).
Evaluate Minimal Residual Disease (MRD) at baseline and follow-up in a clinical study or registry, as appropriate, for the assessment of the anti-leukaemic activity of Ceplene plus low dose Interleukin-2 in a sufficient number of adult patients stratified by age greater or less than 60 years with Acute Myeloid Leukemia in First Complete Remission
Procijeniti minimalnu ostatnu bolest na početku i pratiti u kliničkoj studiji ili registru, kako je odgovarajuće, u svrhu procjene antileukemijske aktivnosti Ceplenea uz nisku dozu interleukina-2 kod dovoljnog broja odraslih bolesnika, stratificiranih prema dobi većoj ili manjoj od 60 godina s akutnom
evaluate pharmacokinetics (PK) of Strensiq in adults following administration of the dose advised in children; provide dose response data on plasma inorganic pyrophosphate (PPi) and pyridoxal- 5` -phosphate (PLP) and to explore evidence of clinical benefit.
procijeniti farmakokinetika (PK) Strensiqa u odraslih bolesnika nakon primjene doze koja se preporučuje za djecu; dobiti podaci o odgovoru na dozu s obzirom na anorganski pirofosfat (PPi) i piridoksal-5`-fosfat (PLP) u plazmi te istražiti dokaz kliničke koristi.
Evaluate the electrolytes every 5–9 days until the Na⁺/K⁺ ratio is < 32, and then administer 2.2 mg/kg of Zycortal.
Procjenjujte elektrolite svakih 5 do 9 dana sve dok omjer Na⁺/K⁺ ne bude < 32, a nakon toga primijenite 2,2 mg/kg Zycortala.
evaluated.
procijenjen.
Evaluation of 6MWD by functional class resulted in a placebo-corrected mean increase from baseline to Month 6 in FC III/IV patients of 37 meters (97.5% CI: 5 to 69) and in FC I/II of 12 meters (97.5% CI: 8 to 33).
Procjena 6MWD po funkcionalnoj klasi u placebom korigiranom prosječnom porastu u odnosu na početnu vrijednost u 6. mjesecu za funkcionalne skupine SZO III/IV od 37 metara (97,5% CI 5 do 69) te u funkcionalnoj skupini I/II od 12 metara (97,5% CI -8 do 33).
Evaluation of brain slides from the carcinogenicity study in rats revealed brain lesions in animals administered high doses of fentanyl citrate.
Pregled rezova mozgova štakora na kojima je ispitivana kancerogenost pokazao je lezije mozga u životinja kojima su davane visoke dize fentanil citrata.